Ladybird homeobox 2 antisense RNA 1 (LBX2-AS1)

Ladybird homeobox 2 antisense RNA 1 (LBX2-AS1) is a long non-coding RNA (lncRNA) found primarily in the cytoplasm, with some presence in the nucleus[1][4]. It does not encode a protein[1] and is located on chromosome 2p13.1[1]. LBX2-AS1 plays a critical role in regulating the expression and stability of the LBX2 gene[3][4]. Extensive research has implicated LBX2-AS1 as an oncogenic factor, contributing to cancer progression by promoting cell proliferation, inhibiting apoptosis, enabling invasion and migration, and mediating drug resistance in various cancer types[1][2][4][5]. Mechanistically, LBX2-AS1 functions both by modulating key signaling pathways, acting as a ceRNA (competing endogenous RNA) to sequester microRNAs and alter downstream oncogenic cascades, and by stabilizing target mRNAs such as LBX2. LBX2-AS1 is positively regulated by several transcription factors, including LBX2 itself, and forms part of a feedback loop critical for its oncogenic activity[1][4]. LBX2-AS1 has been proposed as a promising biomarker for cancer diagnosis and prognosis and is being investigated as a therapeutic target, though no approved drugs currently target this molecule[4][5].

Other names

LBX2 antisense RNA 1LBX2-AS1LBX2 antisense RNA 1 (non-protein coding)Lbx homeobox 2 antisense RNA 1[3]

Not applicable; no drugs currently target LBX2-AS1. However, experimental approaches for targeting LBX2-AS1 include antisense oligonucleotide knockdown or RNA interference to suppress its oncogenic effect, leading to reduced proliferation and increased apoptosis in cancer cells[1][5][4].